We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+3.67%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$450M
AUM Growth
-$279M
Cap. Flow
-$152M
Cap. Flow %
-33.77%
Top 10 Hldgs %
60.29%
Holding
78
New
9
Increased
12
Reduced
27
Closed
29

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$35.2M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$25.3M
3
OSUR icon
OraSure Technologies
OSUR
+$12.9M
4
CTLT
CATALENT, INC.
CTLT
+$11.9M
5
AMRX icon
Amneal Pharmaceuticals
AMRX
+$7.57M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$34M
2
AZN icon
AstraZeneca
AZN
+$27.9M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$23.9M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$15.9M
5
MYOV
Myovant Sciences Ltd.
MYOV
+$15.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.16%
2 Communication Services 1.48%
3 Miscellaneous 1.32%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALGN icon
51
PUT
Align Technology
ALGN
$11.2B
– –
-10,000
Closed -$2.74M
AUTL
52
Autolus Therapeutics
AUTL
$623M
– –
-258,360
Closed -$4.14M
BNR
53
Burning Rock Biotech
BNR
$107M
– –
-3,000
Closed -$810K
CYCN icon
54
Cyclerion Therapeutics
CYCN
$17.7M
– –
-12,383
Closed -$1.46M
CYH icon
55
Community Health Systems
CYH
$413M
– –
-492,272
Closed -$1.48M
CYTK icon
56
Cytokinetics
CYTK
$10B
– –
-141,700
Closed -$3.34M
DVAX
57
DELISTED
Dynavax Technologies
DVAX
– –
-97,800
Closed -$867K
DXCM icon
58
DexCom
DXCM
$34.3B
– –
-26,680
Closed -$2.7M
IMVT icon
59
Immunovant
IMVT
$8.51B
– –
-12,266
Closed -$299K
KNSA icon
60
Kiniksa Pharmaceuticals
KNSA
$6.09B
– –
-81,700
Closed -$2.08M
PCRX icon
61
Pacira BioSciences
PCRX
$1.03B
– –
-132,655
Closed -$6.96M
PNTG icon
62
Pennant Group
PNTG
$1.3B
– –
-102,568
Closed -$2.32M
QURE icon
63
uniQure
QURE
$3.38B
– –
-22,928
Closed -$1.03M
SPY icon
64
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
– –
-340,000
Closed -$105M
XLV icon
65
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$44.5B
– –
-80,000
Closed -$8.01M
XOMA
66
DELISTED
Xoma
XOMA
– –
-64,056
Closed -$1.27M
ZYME icon
67
Zymeworks
ZYME
$2.02B
– –
-40,000
Closed -$1.44M
EIGR
68
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-1,634
Closed -$470K
VAPO
69
DELISTED
Vapotherm, Inc. Common Stock
VAPO
– –
-8,977
Closed -$2.94M
RVLP
70
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
– –
-79,037
Closed -$532K
MYOV
71
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-760,551
Closed -$15.7M
ALBO
72
DELISTED
Albireo Pharma Inc
ALBO
– –
-78,029
Closed -$2.07M
CCXI
73
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-40,842
Closed -$2.35M
RDUS
74
DELISTED
Radius Health, Inc.
RDUS
– –
-220,110
Closed -$3M
DRNA
75
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-128,905
Closed -$3.27M
1 2
3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q3 2020 Portfolio in Review

As of Q3 2020, Eversept Partners held 78 positions worth $450M, down 38% from $729M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Eversept Partners withdrew a net $152M in Q3 2020, closing 29 positions and reducing 27 holdings. Its most notable exit was Myovant Sciences Ltd., an estimated $15.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 81% a quarter earlier, followed by Communication Services and Miscellaneous.

Against the trend, Eversept Partners opened a new position in Teva Pharmaceuticals worth $21.6M.

  • Eversept Partners's largest Q3 2020 buy was Teva Pharmaceuticals: 2,394,355 shares worth $21.6M.
  • Eversept Partners added most to Amarin Corp in Q3 2020, an estimated $35.2M increase.
  • Eversept Partners's biggest Q3 2020 reduction was TG Therapeutics, cutting an estimated $34M.
  • Eversept Partners fully exited Myovant Sciences Ltd. in Q3 2020, selling an estimated $15.7M.
  • Eversept Partners's ten largest holdings make up 60% of its $450M portfolio in Q3 2020.
  • Eversept Partners opened 9 new positions and closed 29 in Q3 2020.
  • Eversept Partners's portfolio value fell 38% quarter-over-quarter to $450M.

Based on Eversept Partners's 13F filing for Q3 2020, filed 12 Nov 2020.